Shares of Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) have received a consensus rating of “Buy” from the sixteen ratings firms that are currently covering the company, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, three have given a hold rating and twelve have assigned a buy rating to the company. The average twelve-month target price among brokerages that have updated their coverage on the stock in the last year is $66.38.

Several brokerages have recently weighed in on AERI. Cowen and Company set a $100.00 price target on Aerie Pharmaceuticals and gave the company a “buy” rating in a research report on Friday, May 26th. Canaccord Genuity set a $65.00 price target on Aerie Pharmaceuticals and gave the company a “buy” rating in a research report on Wednesday, August 16th. Needham & Company LLC lifted their price target on Aerie Pharmaceuticals from $58.00 to $65.00 and gave the company a “buy” rating in a research report on Thursday, May 25th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $62.00 price target (up from $56.00) on shares of Aerie Pharmaceuticals in a research report on Thursday, July 20th. Finally, BidaskClub cut Aerie Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Saturday, June 17th.

Shares of Aerie Pharmaceuticals (NASDAQ:AERI) traded up 1.83% on Wednesday, reaching $58.30. The company’s stock had a trading volume of 961,608 shares. The firm’s 50 day moving average is $54.57 and its 200-day moving average is $49.84. Aerie Pharmaceuticals has a 52-week low of $32.05 and a 52-week high of $60.15. The stock’s market cap is $2.12 billion.

Aerie Pharmaceuticals (NASDAQ:AERI) last issued its earnings results on Tuesday, August 1st. The company reported ($0.82) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.84) by $0.02. On average, equities research analysts forecast that Aerie Pharmaceuticals will post ($2.59) EPS for the current year.

A number of institutional investors have recently bought and sold shares of the stock. Aperio Group LLC grew its position in Aerie Pharmaceuticals by 4.7% during the second quarter. Aperio Group LLC now owns 4,914 shares of the company’s stock worth $258,000 after buying an additional 219 shares in the last quarter. Ameritas Investment Partners Inc. grew its position in Aerie Pharmaceuticals by 11.5% during the second quarter. Ameritas Investment Partners Inc. now owns 2,665 shares of the company’s stock worth $140,000 after buying an additional 275 shares in the last quarter. Legal & General Group Plc grew its position in Aerie Pharmaceuticals by 7.4% during the second quarter. Legal & General Group Plc now owns 7,534 shares of the company’s stock worth $396,000 after buying an additional 519 shares in the last quarter. Bamco Inc. NY grew its position in Aerie Pharmaceuticals by 13.4% during the second quarter. Bamco Inc. NY now owns 5,511 shares of the company’s stock worth $290,000 after buying an additional 653 shares in the last quarter. Finally, The Manufacturers Life Insurance Company grew its position in Aerie Pharmaceuticals by 5.5% during the second quarter. The Manufacturers Life Insurance Company now owns 23,501 shares of the company’s stock worth $1,235,000 after buying an additional 1,235 shares in the last quarter. Institutional investors and hedge funds own 94.64% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This report was first reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this report on another domain, it was copied illegally and reposted in violation of United States & international trademark and copyright laws. The legal version of this report can be accessed at https://www.thecerbatgem.com/2017/09/16/brokerages-set-aerie-pharmaceuticals-inc-aeri-target-price-at-66-38.html.

About Aerie Pharmaceuticals

Aerie Pharmaceuticals, Inc is a clinical-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. The Company’s product candidates include Rhopressa (netarsudil ophthalmic solution) 0.02% (Rhopressa), and Roclatan (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005% (Roclatan).

Analyst Recommendations for Aerie Pharmaceuticals (NASDAQ:AERI)

Receive News & Stock Ratings for Aerie Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aerie Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.